solution vehicle-Pfizer-onychomycosis

The solution vehicle-Pfizer-onychomycosis is an inactive topical solution used as a vehicle control (placebo) in Phase 3 clinical trials for tavaborole (AN2690), an antifungal treatment for onychomycosis. Developed by Anacor Pharmaceuticals (later acquired by Pfizer), the vehicle contains the same excipients as the active 5% topical solution—typically including alcohol, ethyl acetate, and propylene glycol—but lacks the active pharmaceutical ingredient, tavaborole. In Phase 3 trials (e.g., NCT01270971 and NCT01256996), it was used as a comparator to evaluate the efficacy and safety of tavaborole in adults with distal subungual onychomycosis of the toenail. As a placebo, it has no therapeutic antifungal activity and demonstrated significantly lower cure rates compared to the active tavaborole treatment.

Other names

tavaborole vehicleAN2690 Topical Solution, Vehicle